News Penumbra, Inc.

Equities

PEN

US70975L1070

Market Closed - Nyse Other stock markets 16:00:02 2024-04-26 EDT			5-day change	1st Jan Change
204.4 ^USD	-0.53%		+0.83%	-18.74%

04-23	Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	CI
04-17	DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	04-23	PR
Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	04-23	CI
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	04-17	MT
Penumbra, Inc. : The underdog in healthcare	04-11
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024	04-09	PR
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	03-27	MT
Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating	03-22	MT
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating	02-26	MT
North American Morning Briefing : Traders Await -2-	02-26	DJ
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating	02-23	MT
Truist Securities Cuts Price Target on Penumbra to $290 From $300, Maintains Buy Rating	02-23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	02-23	MT
JPMorgan Downgrades Penumbra to Neutral From Overweight, Cuts Price Target to $250 From $284	02-23	MT
Penumbra Q4 Non-GAAP EPS, Revenue Increase; Shares Fall After-Hours	02-22	MT
Penumbra: Q4 Earnings Snapshot	02-22	AQ
Transcript : Penumbra, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Earnings Flash (PEN) PENUMBRA Posts Q4 Revenue $284.7M, vs. Street Est of $286.5M	02-22	MT
Earnings Flash (PEN) PENUMBRA Reports Q4 EPS $0.76, vs. Street Est of $0.70	02-22	MT
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results	02-22	PR
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024	02-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Penumbra, Inc. : The underdog in healthcare

April 11, 2024 at 09:39 pm